PL3762018T3 - Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą - Google Patents

Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą

Info

Publication number
PL3762018T3
PL3762018T3 PL19721159.2T PL19721159T PL3762018T3 PL 3762018 T3 PL3762018 T3 PL 3762018T3 PL 19721159 T PL19721159 T PL 19721159T PL 3762018 T3 PL3762018 T3 PL 3762018T3
Authority
PL
Poland
Prior art keywords
alkaline phosphatase
kidney injury
acute kidney
treating sepsis
associated acute
Prior art date
Application number
PL19721159.2T
Other languages
English (en)
Inventor
Roelof Peter Pickkers
Ravindra Lall MEHTA
Patrick Thomas Murray
Michael JOANNIDIS
Erik Jan VAN DEN BERG
Jacques Salomon Robert AREND
Original Assignee
Am-Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B.V. filed Critical Am-Pharma B.V.
Publication of PL3762018T3 publication Critical patent/PL3762018T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL19721159.2T 2018-03-08 2019-03-08 Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą PL3762018T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640494P 2018-03-08 2018-03-08
PCT/NL2019/050153 WO2019172766A1 (en) 2018-03-08 2019-03-08 Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury

Publications (1)

Publication Number Publication Date
PL3762018T3 true PL3762018T3 (pl) 2024-06-17

Family

ID=66349613

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19721159.2T PL3762018T3 (pl) 2018-03-08 2019-03-08 Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą

Country Status (15)

Country Link
US (2) US12178857B2 (pl)
EP (2) EP4342534A3 (pl)
JP (2) JP7502994B2 (pl)
CN (1) CN112261948B (pl)
AU (1) AU2019232395B2 (pl)
CA (1) CA3093040A1 (pl)
DK (1) DK3762018T3 (pl)
ES (1) ES2978165T3 (pl)
FI (1) FI3762018T3 (pl)
IL (1) IL277088B2 (pl)
MX (1) MX2020009002A (pl)
PL (1) PL3762018T3 (pl)
PT (1) PT3762018T (pl)
RU (1) RU2020129445A (pl)
WO (1) WO2019172766A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES2978165T3 (es) 2018-03-08 2024-09-06 Am Pharma Bv Fosfatasa alcalina recombinante para uso en el tratamiento de la lesión renal aguda asociada a la sepsis
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
NL2025730B1 (en) 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
CN121038803A (zh) * 2023-03-21 2025-11-28 安-法玛公司 用于治疗慢加急性肾损伤的碱性磷酸酶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
ES2828987T3 (es) 2011-06-08 2021-05-28 Am Pharma Bv El uso de fosfatasa alcalina para preservar la función renal
CN111778228A (zh) 2014-01-24 2020-10-16 安-法玛公司 嵌合型碱性磷酸酶样蛋白
WO2015160805A1 (en) 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
ES2978165T3 (es) 2018-03-08 2024-09-06 Am Pharma Bv Fosfatasa alcalina recombinante para uso en el tratamiento de la lesión renal aguda asociada a la sepsis

Also Published As

Publication number Publication date
EP4342534A3 (en) 2024-05-22
DK3762018T3 (da) 2024-05-06
US20200397870A1 (en) 2020-12-24
NZ768111A (en) 2024-08-30
RU2020129445A (ru) 2022-04-08
WO2019172766A1 (en) 2019-09-12
EP3762018A1 (en) 2021-01-13
EP4342534A2 (en) 2024-03-27
US12178857B2 (en) 2024-12-31
FI3762018T3 (fi) 2024-04-22
CN112261948A (zh) 2021-01-22
JP7502994B2 (ja) 2024-06-19
ES2978165T3 (es) 2024-09-06
PT3762018T (pt) 2024-05-07
JP2021515022A (ja) 2021-06-17
IL277088A (en) 2020-10-29
MX2020009002A (es) 2021-02-15
JP2022078186A (ja) 2022-05-24
AU2019232395A1 (en) 2020-10-15
AU2019232395B2 (en) 2025-01-23
IL277088B1 (en) 2023-12-01
CA3093040A1 (en) 2019-09-12
EP3762018B1 (en) 2024-02-14
CN112261948B (zh) 2024-06-25
IL277088B2 (en) 2024-04-01
US20250222077A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
IL277088A (en) Recombinant alkaline phosphatase for use in the treatment of acute kidney injury associated with sepsis
GB2589223B (en) Component-dependent sub-block dividing
SG11202104356VA (en) Bt1718 for use in treating cancer
IL279757A (en) Probucol for the use and treatment of mitochondrial electron transport chain dysfunction
SG11202102228TA (en) Configuration enhancement in handover
SG11201905878QA (en) Identity document verification
GB201813876D0 (en) Treatment
SMT202400334T1 (it) (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
IL274630A (en) Emulsions for the treatment of mucosal infections
SI3288588T1 (sl) Izboljšana sredstva za prečno povezovanje kolagenskih vlaken za uporabo pri zdravljenju kornealne ektazije
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
IL288900A (en) Treatment including fxr agonists
IL280368A (en) Compounds for use in the treatment of kidney disorders
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
SG11202010528XA (en) Combinations for treating cancer
GB201800546D0 (en) Treatment
LT3406258T (lt) Vaistas, skirtas podagros gydymui
GB201821147D0 (en) Mirna for use in therapy
ZA201904031B (en) Identity document verification
GB2577191B (en) System for use in improving cognitive function
PL3291691T3 (pl) Wykorzystanie azotanów w leczeniu poporodowej dysgalakcji u ssaków jednożołądkowych
IL285538A (en) Combined therapies for use in cancer treatment
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
ZA201907017B (en) Combination therapy for use in treating retroviral infection
SG11202012889QA (en) Dosing regimens for treating hypoxia-associated tissue damage